No exact match found for Karachaliou, Niki,, using Karachaliou Niki instead...
UAB Digital Repository of Documents 7 records found  Search took 0.01 seconds. 
1.
13 p, 828.8 KB Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions / Villatoro, Sergi (Grup Quirónsalud (Barcelona, Catalunya)) ; Mayo-de-las-Casas, Clara (Grup Quirónsalud (Barcelona, Catalunya)) ; Jordana-Ariza, Núria (Grup Quirónsalud (Barcelona, Catalunya)) ; Viteri-Ramírez, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ; Garzón-Ibañez, Mónica (Grup Quirónsalud (Barcelona, Catalunya)) ; Moya-Horno, Irene (Hospital General de Catalunya) ; García-Peláez, Beatrtiz (Grup Quirónsalud (Barcelona, Catalunya)) ; González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ; Malapelle, Umberto (University of Naples Federico II) ; Balada-Bel, Ariadna (Grup Quirónsalud (Barcelona, Catalunya)) ; Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ; Campos, Raquel (Grup Quirónsalud (Barcelona, Catalunya)) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Blanco, Remei (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Blasco, Ana (Hospital General Universitari de València) ; Catalán, María J. (Grup Quirónsalud (Barcelona, Catalunya)) ; González, Xavier (Hospital General de Catalunya) ; Troncone, Giancarlo (University of Naples Federico II) ; Karachaliou, Niki (Hospital del Sagrat Cor (Barcelona, Catalunya)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Molina-Vila, Miguel Ángel (Grup Quirónsalud (Barcelona, Catalunya)) ; Universitat Autònoma de Barcelona
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations and guide treatment decisions. [...]
2019 - 10.1002/1878-0261.12574
Molecular Oncology, Vol. 13 Núm. 12 (january 2019) , p. 2633-2645  
2.
11 p, 2.1 MB Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma / Ito, Masaoki (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Codony-Servat, Jordi (Institut Universitari Dexeus) ; Giménez-Capitán, Ana (Institut Universitari Dexeus) ; Serra-Mitjans, Mireia (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Pérez-Ochoa, Francisco (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Llige, David (Institut Germans Trias i Pujol) ; Chaib, Imane (Institut Germans Trias i Pujol) ; Rami-Porta, Ramon (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Obiols, Carme (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Call, Sergi (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Iglesias, Manuela (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Belda, José (Belda Sanchis) (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Tarroch-Sarasa, Xavier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Karachaliou, Niki (Institut Universitari Dexeus) ; Molina-Vila, Miguel Ángel (Institut Universitari Dexeus) ; Okada, Morihito (Hiroshima University. Department of Surgical Oncology) ; Rosell, Rafael (Institut Germans Trias i Pujol)
EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be predictive in patients positive with resected EGFR mutation versus patients with EGFR wild-type LUAD. [...]
2020 - 10.1016/j.jtocrr.2020.100084
JTO Clinical and Research Reports, Vol. 1 Núm. 4 (august 2020)  
3.
13 p, 2.9 MB BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial : The need for a new pre-clinical treatment rationale / Bracht, Jillian (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Karachaliou, Niki (Hospital Universitari Sagrat Cor. Institut Oncològic Rosell) ; Bivona, Trever (University of California. Department of Medicine) ; Lanman, Richard B. (Guardant Health) ; Faull, Iris (Guardant Health) ; Nagy, Rebecca J. (Guardant Health) ; Drozdowskyj, Ana (PIVOTAL SL) ; Berenguer, Jordi (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ; Fernandez-Bruno, Manuel (Hospital Universitario Sagrat Cor. Institut Oncològic Rosell) ; Molina-Vila, Miguel Ángel (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
BRAF V600 mutations have been found in 1-2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10. [...]
2019 - 10.3390/cancers11091381
Cancers, Vol. 11, Issue 9 (September 2019) , art. 1381  
4.
161 p, 2.3 MB Carcinoma de pulmón no celula pequeña, con mutación de KRas : diferenciación y caracterización de subtipos, así como de los diferentes mecanismos de resistencia, para la elaboración de tratamientos dirigidos / Gil Moreno, María de los Llanos ; Rosell, Rafael, dir. ; Karachaliou, Niki, dir. ; Feliu Frasnedo, Evarist, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
Introducción: El cáncer de pulmón es el tercer tumor más frecuente y produce más de 20. 000 muertes al año en España. Pese a los avances en oncología, la quimioterapia e inmunoterapia son los únicos tratamientos para pacientes con mutación de KRAS, con resultados subóptimos. [...]
Introduction: Lung cancer is the 3rd most frequent tumor and produces more than 20,000 deaths per year in Spain. Despite recent advances in oncology chemotherapy, and inmunotherapy remains the only remedy for patients whose tumor is driven by RAS mutations, with suboptimal results. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2019.  
5.
12 p, 1.4 MB Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC / Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ; Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ; Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ; Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Drozdowskyj, Ana (Pivotal, Madrid) ; Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ; Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Cardona Zorrilla, Andrés Felipe (Clinica del Country, Bogotá) ; Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Sanchez, Jose Miguel (Hospital Universitario de la Princesa (Madrid)) ; Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ; Teixidó, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ; Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ; Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ; Aguirre, Itziar de (Institut Germans Trias i Pujol) ; Queralt, C (Institut Germans Trias i Pujol) ; Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol) ; Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ; Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ; Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Bivona, Trever (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12  
6.
8 p, 615.1 KB Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis / Bria, Emilio (Azienda Ospedaliera Universitaria Integrata (Verona, Itàlia)) ; Pilotto, Sara (Azienda Ospedaliera Universitaria Integrata (Verona, Itàlia)) ; Simbolo, M. (Università di Verona) ; Fassan, M. (Università di Verona) ; De Manzoni, G.. (Università di Verona) ; Carbognin, L. (Azienda Ospedaliera Universitaria Integrata (Verona, Itàlia)) ; Sperduti, Isabella (Istituto Regina Elena (Roma, Itàlia)) ; Brunelli, M. (Università di Verona) ; Cataldo, I. (Università di Verona) ; Tomezzoli, A. (Università di Verona) ; Mafficini, A. (Università di Verona) ; Turri, G. (Università di Verona) ; Karachaliou, Niki (Pangaea Biotech (Barcelona, Catalunya)) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tortora, G. (Azienda Ospedaliera Universitaria Integrata (Verona, Itàlia)) ; Scarpa, A. (Università di Verona)
In this study, we evaluated whether the presence of genetic alterations detected by next generation sequencing may define outcome in a prognostically-selected and histology-restricted population of resected gastric cancer (RGC). [...]
2016 - 10.1038/srep22982
Scientific reports, Vol. 6 (Marz 2016)  
7.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)  

See also: similar author names
2 Karachaliou, N.
6 Karachaliou, Niki
6 Karachaliou, Niki
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.